CL2020000363A1 - Inhibidores macrocíclicos de mcl-1 y métodos de uso. - Google Patents

Inhibidores macrocíclicos de mcl-1 y métodos de uso.

Info

Publication number
CL2020000363A1
CL2020000363A1 CL2020000363A CL2020000363A CL2020000363A1 CL 2020000363 A1 CL2020000363 A1 CL 2020000363A1 CL 2020000363 A CL2020000363 A CL 2020000363A CL 2020000363 A CL2020000363 A CL 2020000363A CL 2020000363 A1 CL2020000363 A1 CL 2020000363A1
Authority
CL
Chile
Prior art keywords
inhibitors
methods
mcl
macrocyclic
macrocyclic mcl
Prior art date
Application number
CL2020000363A
Other languages
English (en)
Inventor
Zhi-Fu Tao
Xilu Wang
Aaron Kunzer
Gerard Sullivan
Wilfried Braje
George Doherty
Katja Jantos
Cheng Ji
Andrew Judd
Anthony Mastracchio
Xiaohong Song
Andrew Souers
Jesse Teske
Michael Wendt
Thomas Penning
Andreas Kling
Frauke Pohlki
Chunqiu Lai
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of CL2020000363A1 publication Critical patent/CL2020000363A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE DIVULGACIÓN SE REFIERE A INHIBIDORES DE LA PROTEÍNA DE DIFERENCIACIÓN CELULAR DE LEUCEMIA 5 MIELOIDE INDUCIDA (MCL-1), EN DONDE A2, A3, A4, A6, A7, A8, A15, RA, R5, R10A, R10B, R11, R12, R13, R14, W, X, E Y TIENEN CUALQUIERA DE LOS VALORES DEFINIDOS EN LA MEMORIA DESCRIPTIVA, Y SALES ACEPTABLES DESDE EL PUNTO DE VISTA FARMACÉUTICO DE ESTOS , QUE SON ÚTILES COMO AGENTES EN EL TRATAMIENTO DE ENFERMEDADES Y AFECCIONES, INCLUIDO EL CÁNCER. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE LA FÓRMULA (I) .
CL2020000363A 2017-08-15 2020-02-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso. CL2020000363A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545853P 2017-08-15 2017-08-15
US201762555475P 2017-09-07 2017-09-07
US201862692663P 2018-06-30 2018-06-30

Publications (1)

Publication Number Publication Date
CL2020000363A1 true CL2020000363A1 (es) 2020-06-12

Family

ID=65362347

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020000363A CL2020000363A1 (es) 2017-08-15 2020-02-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso.
CL2020002943A CL2020002943A1 (es) 2017-08-15 2020-11-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020002943A CL2020002943A1 (es) 2017-08-15 2020-11-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020

Country Status (21)

Country Link
US (3) US10676485B2 (es)
EP (2) EP3652184A4 (es)
JP (1) JP2020531433A (es)
KR (1) KR20200041942A (es)
CN (1) CN111818917A (es)
AU (1) AU2018316620A1 (es)
BR (1) BR112020003180A2 (es)
CA (1) CA3073112A1 (es)
CL (2) CL2020000363A1 (es)
CO (1) CO2020002678A2 (es)
CR (1) CR20200124A (es)
EC (1) ECSP20018703A (es)
IL (1) IL272681A (es)
MX (1) MX2020001717A (es)
PH (1) PH12020500327A1 (es)
RU (1) RU2020110517A (es)
SG (2) SG10202106345VA (es)
TW (1) TW201920194A (es)
UA (1) UA126586C2 (es)
UY (1) UY37843A (es)
WO (1) WO2019035911A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11414390B2 (en) 2017-09-07 2022-08-16 Hutchison Medipharma Limited Cycloolefin substituted heteroaromatic compounds and their use
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111818917A (zh) * 2017-08-15 2020-10-23 艾伯维公司 大环mcl-1抑制剂和使用方法
TW201920193A (zh) * 2017-08-15 2019-06-01 美商艾伯維有限公司 大環ｍｅｌ-１抑制劑以及使用方法
WO2019035865A1 (en) 2017-08-15 2019-02-21 Agios Pharmaceuticals Inc. MODULATORS OF PYRUVATE KINASE AND THEIR USE
US20200255451A1 (en) * 2017-08-15 2020-08-13 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
KR20220017931A (ko) 2019-05-20 2022-02-14 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
WO2022115451A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
TW202315637A (zh) 2021-06-11 2023-04-16 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
TW202317200A (zh) 2021-06-11 2023-05-01 美商基利科學股份有限公司 Ｍｃｌ－１抑制劑與抗體藥物接合物之組合
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2276346B1 (en) * 2008-04-30 2016-11-23 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CR20180499A (es) 2016-04-22 2019-01-25 Astrazeneca Ab Inhibidores de mcl1 macrocicliclos para tratar el cancer
TWI759316B (zh) 2016-07-22 2022-04-01 法商施維雅藥廠 Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
LT3532067T (lt) 2016-10-28 2022-08-25 Les Laboratoires Servier Liposominė vaisto forma, skirta naudoti gydant vėžį
EP3567043B1 (en) 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
TW201920193A (zh) * 2017-08-15 2019-06-01 美商艾伯維有限公司 大環ｍｅｌ-１抑制劑以及使用方法
CN111818917A (zh) * 2017-08-15 2020-10-23 艾伯维公司 大环mcl-1抑制剂和使用方法
US20200255451A1 (en) 2017-08-15 2020-08-13 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
CN107573360B (zh) 2017-10-27 2019-08-09 都创(上海)医药科技有限公司 一种多靶点小分子化合物s63845的制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11414390B2 (en) 2017-09-07 2022-08-16 Hutchison Medipharma Limited Cycloolefin substituted heteroaromatic compounds and their use
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Also Published As

Publication number Publication date
US10676485B2 (en) 2020-06-09
IL272681A (en) 2020-03-31
RU2020110517A3 (es) 2022-03-23
EP3652184A1 (en) 2020-05-20
KR20200041942A (ko) 2020-04-22
CN111818917A (zh) 2020-10-23
PH12020500327A1 (en) 2020-10-12
US20190144465A1 (en) 2019-05-16
SG11202001182QA (en) 2020-03-30
BR112020003180A2 (pt) 2020-09-15
TW201920194A (zh) 2019-06-01
RU2020110517A (ru) 2021-09-16
UA126586C2 (uk) 2022-11-02
ECSP20018703A (es) 2020-04-22
WO2019035911A1 (en) 2019-02-21
CL2020002943A1 (es) 2021-03-12
EP3652184A4 (en) 2020-05-20
MX2020001717A (es) 2020-10-08
EP3988555A1 (en) 2022-04-27
JP2020531433A (ja) 2020-11-05
CO2020002678A2 (es) 2020-08-10
CA3073112A1 (en) 2019-02-21
SG10202106345VA (en) 2021-07-29
US20200325153A1 (en) 2020-10-15
UY37843A (es) 2019-03-29
US20230183261A1 (en) 2023-06-15
AU2018316620A1 (en) 2020-03-12
CR20200124A (es) 2020-09-28

Similar Documents

Publication Publication Date Title
CL2020000363A1 (es) Inhibidores macrocíclicos de mcl-1 y métodos de uso.
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
DOP2022000117A (es) Inhibidores de kras g12c
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CO2018011064A2 (es) Inhibidores de bromodominios
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
DOP2015000305A (es) Inhibidores de bromodominios
UY37842A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
MX2017007748A (es) Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk).
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
UY37844A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
MX2015012005A (es) Inhibidores de bromodominio.
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CY1121060T1 (el) Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση
MX2019004375A (es) Inhibidores de bromodominios.
MX2019004187A (es) Inhibidores de bromodominios.
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1